Pricing Log in Create free account

Neuraxis, Inc. (NRXS) vs Unicycive Therapeutics, Inc. (UNCY)

Neuraxis, Inc. and Unicycive Therapeutics, Inc. are both Biotechnology companies. Neuraxis, Inc. and Unicycive Therapeutics, Inc. are of similar size ($100.0M and $97.2M). Unicycive Therapeutics, Inc. has the higher net margin (0.00% vs −159.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Unicycive Therapeutics, Inc. leads on 8 and Neuraxis, Inc. on 4.

Valuation

Metric NRXS UNCY Biotechnology median
P/E n/m n/m 8.50
P/S 17.55 n/m 9.71
P/B 13.86 1.70 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 16.00 n/m 9.21
Earnings yield (10.13%) (52.08%) (33.15%)
Free cash flow yield (6.20%) (30.79%) (25.50%)

Profitability

Metric NRXS UNCY Biotechnology median
Gross margin 85.56% 0.00% 65.16%
Operating margin (144.51%) 0.00% 0.00%
Net margin (159.01%) 0.00% 0.00%
Free cash flow margin (106.10%) 0.00% 0.00%
Return on equity (153.96%) (101.07%) (56.36%)
Return on assets (98.96%) (69.05%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NRXS UNCY Biotechnology median
Revenue growth (TTM) 65.22% — 6.02%
EPS growth (last fiscal year) 22.13% 70.18% 30.26%
Revenue growth, 5-year CAGR 13.08% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NRXS UNCY Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.04 3.81 4.72
Net debt to EBITDA 0.64 1.43 0.96

Dividend

Metric NRXS UNCY Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric NRXS UNCY Biotechnology median
Market cap 97.19m 100.00m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack